Insider · CIK 0001398940
Arturo Molina Md
officer
Files at PTGX (Protagonist Therapeutics, Inc). First filing Nov 19, 2024, latest Mar 27, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 7
$0 bought, $7.1M sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
PTGX: Protagonist Therapeutics, Inc
PTGXOct 9, 2026 · close 143.73
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 38Weak | Protagonist Therapeutics, Inc | $1.6M 15,000 shares | -15% | +150% from low-2% from high | |
| 38Weak | Protagonist Therapeutics, Inc | $1.9M 23,151 shares | -24% | +137% from low-13% from high | |
| 45Moderate | Protagonist Therapeutics, Inc | $785k 9,514 shares | -9% | +138% from low-13% from high | |
| 28Weak | PTGXsell Protagonist Therapeutics, Inc | $230k 2,712 shares | -3% | +142% from low-3% from high | |
| 30Weak | PTGXsell Protagonist Therapeutics, Inc | $1.1M 20,000 shares | -21% | +59% from low-7% from high | |
| 60Notable | Protagonist Therapeutics, Inc | $1.4M 31,529 shares | -61% | - | |
| 39Weak | Protagonist Therapeutics, Inc | $78k 1,906 shares | -4% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | PTGX Protagonist Therapeutics, Inc | MOption exercise Common Stock | +15,000 | $8.04 | $121k | 99,115 | Mar 27, 2026 |
| Mar 26, 2026 | PTGX Protagonist Therapeutics, Inc | SOpen-market sale Common Stock | -15,000 | $104.79 | $1.6M | 84,115 | Mar 27, 2026 |
| Mar 26, 2026 | PTGX Protagonist Therapeutics, Inc | MOption exercise Stock Option (right to buy)derivative | -15,000 | $0.00 | $0 | 50,971 | Mar 27, 2026 |
| Jan 23, 2026 | PTGX Protagonist Therapeutics, Inc | SOpen-market sale Common Stock | -13,151 | $82.42 | $1.1M | 84,115 | Jan 27, 2026 |
| Jan 26, 2026 | PTGX Protagonist Therapeutics, Inc | MOption exercise Common Stock | +5,000 | $8.04 | $40k | 89,115 | Jan 27, 2026 |
| Jan 26, 2026 | PTGX Protagonist Therapeutics, Inc | SOpen-market sale Common Stock | -5,000 | $82.28 | $411k | 84,115 | Jan 27, 2026 |
| Jan 27, 2026 | PTGX Protagonist Therapeutics, Inc | MOption exercise Common Stock | +5,000 | $8.04 | $40k | 89,115 | Jan 27, 2026 |
| Jan 27, 2026 | PTGX Protagonist Therapeutics, Inc | SOpen-market sale Common Stock | -5,000 | $82.00 | $410k | 84,115 | Jan 27, 2026 |
| Jan 26, 2026 | PTGX Protagonist Therapeutics, Inc | MOption exercise Stock Option (right to buy)derivative | -5,000 | $0.00 | $0 | 70,971 | Jan 27, 2026 |
| Jan 27, 2026 | PTGX Protagonist Therapeutics, Inc | MOption exercise Stock Option (right to buy)derivative | -5,000 | $0.00 | $0 | 65,971 | Jan 27, 2026 |
| Jan 20, 2026 | PTGX Protagonist Therapeutics, Inc | SOpen-market sale Common Stock | -9,514 | $82.48 | $785k | 97,266 | Jan 21, 2026 |
| Jan 2, 2026 | PTGX Protagonist Therapeutics, Inc | AGrant or award Common Stock | +25,600 | $0.00 | $0 | 106,780 | Jan 6, 2026 |
| Jan 2, 2026 | PTGX Protagonist Therapeutics, Inc | AGrant or award Stock Option (right to buy)derivative | +32,000 | $0.00 | $0 | 32,000 | Jan 6, 2026 |
| Nov 17, 2025 | PTGX Protagonist Therapeutics, Inc | SOpen-market sale Common Stock | -2,712 | $84.77 | $230k | 81,180 | Nov 19, 2025 |
| Jun 9, 2025 | PTGX Protagonist Therapeutics, Inc | MOption exercise Common Stock | +10,000 | $8.04 | $80k | 93,892 | Jun 11, 2025 |
| Jun 9, 2025 | PTGX Protagonist Therapeutics, Inc | SOpen-market sale Common Stock | -10,000 | $55.51 | $555k | 83,892 | Jun 11, 2025 |
| Jun 10, 2025 | PTGX Protagonist Therapeutics, Inc | MOption exercise Common Stock | +10,000 | $8.04 | $80k | 93,892 | Jun 11, 2025 |
| Jun 10, 2025 | PTGX Protagonist Therapeutics, Inc | SOpen-market sale Common Stock | -10,000 | $57.03 | $570k | 83,892 | Jun 11, 2025 |
| Jun 9, 2025 | PTGX Protagonist Therapeutics, Inc | MOption exercise Stock Option (right to buy)derivative | -10,000 | $0.00 | $0 | 85,971 | Jun 11, 2025 |
| Jun 10, 2025 | PTGX Protagonist Therapeutics, Inc | MOption exercise Stock Option (right to buy)derivative | -10,000 | $0.00 | $0 | 75,971 | Jun 11, 2025 |
| Nov 26, 2024 | PTGX Protagonist Therapeutics, Inc | MOption exercise Common Stock | +5,529 | $8.04 | $44k | 51,973 | Nov 27, 2024 |
| Nov 26, 2024 | PTGX Protagonist Therapeutics, Inc | SOpen-market sale Common Stock | -5,529 | $45.60 | $252k | 46,444 | Nov 27, 2024 |
| Nov 27, 2024 | PTGX Protagonist Therapeutics, Inc | MOption exercise Common Stock | +10,000 | $8.04 | $80k | 56,444 | Nov 27, 2024 |
| Nov 27, 2024 | PTGX Protagonist Therapeutics, Inc | SOpen-market sale Common Stock | -10,000 | $44.50 | $445k | 46,444 | Nov 27, 2024 |
| Nov 27, 2024 | PTGX Protagonist Therapeutics, Inc | MOption exercise Common Stock | +16,000 | $8.04 | $129k | 62,444 | Nov 27, 2024 |
| Nov 27, 2024 | PTGX Protagonist Therapeutics, Inc | SOpen-market sale Common Stock | -16,000 | $44.83 | $717k | 46,444 | Nov 27, 2024 |
| Nov 26, 2024 | PTGX Protagonist Therapeutics, Inc | MOption exercise Stock Option (right to buy)derivative | -5,529 | $0.00 | $0 | 121,971 | Nov 27, 2024 |
| Nov 27, 2024 | PTGX Protagonist Therapeutics, Inc | MOption exercise Stock Option (right to buy)derivative | -10,000 | $0.00 | $0 | 111,971 | Nov 27, 2024 |
| Nov 27, 2024 | PTGX Protagonist Therapeutics, Inc | MOption exercise Stock Option (right to buy)derivative | -16,000 | $0.00 | $0 | 95,971 | Nov 27, 2024 |
| Nov 15, 2024 | PTGX Protagonist Therapeutics, Inc | SOpen-market sale Common Stock | -1,906 | $40.98 | $78k | 46,444 | Nov 19, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.